Lv3
325 积分 2020-09-16 加入
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
8天前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
20天前
已完结
Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer
21天前
已完结
[Expert panel consensus on pathological diagnosis of breast cancer with neoadjuvant therapy, the 2020 version]
1个月前
已完结
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials
2个月前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
3个月前
已完结
Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study
4个月前
已完结
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial
5个月前
已完结
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
5个月前
已完结
皖公网安备34019202002308
